Pembrolizumab Versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase 3 KEYNOTE-177 study.

Autor:	André T; Department of Medical Oncology, Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM 938, SIRIC CURAMUS, Paris, France. Electronic address: thierry.andre@aphp.fr., Shiu KK; Department of Medical Oncology, University College Hospital, NHS Foundation Trust, London, UK., Kim TW; Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, South Korea., Jensen BV; Department of Medical Oncology, Herlev and Gentofte Hospital, Herlev, Denmark., Jensen LH; Department of Oncology, University Hospital of Southern Denmark, Vejle, Denmark., Punt CJA; Department of Medical Oncology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., Smith D; Department of Oncology, Bordeaux University Hospital, Bordeaux, France., Garcia-Carbonero R; Department of Oncology, University Hospital October 12, Imas12, School of Medicine, UCM, Madrid, Spain., Alcaide-Garcia J; Regional University Hospital of Malaga, IBIMA, Málaga, Spain., Gibbs P; Department of Medical Oncology-Colorectal Cancer, Western Health, St Albans, VIC, Australia., Fouchardiere C; Department of Medical Oncology, Léon Bérard Center, Lyon, France., Rivera F; Department of Oncology, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain., Elez E; Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology, Autonomous University of Barcelona, Barcelona, Spain., Le DT; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA., Yoshino T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Zuo Y; Department of Statistics, MSD China, Beijing, China., Fogelman D; Department of Medical Oncology, Merck & Co., Inc., Rahway, NJ, USA., Adelberg D; Department of Medical Oncology, Merck & Co., Inc., Rahway, NJ, USA., Diaz LA Jr; Department of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: diazl5@mskcc.org.
Jazyk:	angličtina
Zdroj:	Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Dec 02. Date of Electronic Publication: 2024 Dec 02.
DOI:	10.1016/j.annonc.2024.11.012
Abstrakt:	Background: Results from the phase 3 KEYNOTE-177 study established pembrolizumab as a new first-line standard of care for microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Previous results from KEYNOTE-177 showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with pembrolizumab versus chemotherapy ± bevacizumab/cetuximab in MSI-H/dMMR mCRC. Results after >5 years of follow-up are reported. Patients and Methods: Adults with untreated MSI-H/dMMR mCRC were randomly assigned 1:1 to receive pembrolizumab 200 mg intravenously every 3 weeks or chemotherapy. Patients assigned to chemotherapy could cross over to pembrolizumab after centrally confirmed progressive disease. Dual primary end points were PFS per RECIST v1.1 and overall survival (OS). Secondary end points included duration of response (DOR) and safety. Results: At data cutoff (July 17, 2023), median follow-up was 73.3 months (range, 64.9-89.2). Overall, 307 patients were assigned to receive pembrolizumab (n=153) or chemotherapy (n=154). Fifty-seven (37.0%) patients assigned to chemotherapy crossed over to pembrolizumab per protocol; 39 (25.3%) received a PD-(L)1 inhibitor off protocol (effective crossover rate, 62%). Median OS was 77.5 months with pembrolizumab versus 36.7 months with chemotherapy (hazard ratio [HR], 0.73; 95% CI, 0.53-0.99); 5-year OS rates were 54.8% versus 44.2%. Median PFS was 16.5 months with pembrolizumab and 8.2 months with chemotherapy (HR, 0.60; 95% CI, 0.45-0.79). Median DOR was 75.4 months (range, 2.3+ to 80.1+) with pembrolizumab versus 10.6 months (range, 2.8 to 71.5+) with chemotherapy. Compared with chemotherapy, fewer patients in the pembrolizumab arm experienced adverse events (80% versus 99%; grade 3-5, 22% versus 67%). Conclusions: With >5 years of follow-up, responses to pembrolizumab remained durable. Median OS was over twice as long in patients treated with pembrolizumab versus chemotherapy in first line despite an effective crossover rate of 62%. Pembrolizumab remains a standard of care for MSI-H/dMMR mCRC. (Copyright © 2024 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu